Loading...
XLONCNSL
Market cap5mUSD
Oct 13, Last price  
1.75GBP
Name

Omega Diagnostics Group PLC

Chart & Performance

D1W1MN
XLON:CNSL chart
P/E
—
P/S
55.12
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
13.27%
Rev. gr., 5y
-11.05%
Revenues
8m
-11.63%
0003,492,0005,438,0006,199,0007,902,00011,124,00011,262,89811,593,87012,105,31912,743,89614,246,93013,552,7268,756,7569,818,6628,734,8638,539,0007,546,000
Net income
-4m
L+173.95%
-73,000-85,0000238,000221,000187,00031,000527,000582,266692,851739,046571,912713,261-7,269,597974,253-6,828,312-2,104,310-1,409,000-3,860,000
CFO
-3m
L-2.38%
-63,000-78,000311,000600,000170,000322,000673,0001,014,9531,669,1071,247,8931,453,6762,011,324-828,497368,819547,607-2,419,589-3,229,000-3,152,000

Profile

Omega Diagnostics Group PLC, through its subsidiaries, develops, manufactures, and distributes medical diagnostics products in the United Kingdom, rest of Europe, North America, South/Central America, India, other Asian countries and the Far East, Africa, and the Middle East. The company operates through two segments, Health and Nutrition, and Global Health and Other. The Health and Nutrition segment engages in the research, development, and production of kits to aid the detection of immune reactions to food under the Foodprint name. This segment also provides clinical analysis to the general public, clinics, and health professionals, as well as supplies Food Detective, a consumer food test. The Global Health and Other segment engages in the research, development, production, and marketing of kits that are used in the diagnosis of infectious diseases. This segment offers VISITECT CD4, an advanced disease rapid test, which is used to treat patients with HIV; and AbC-19, a COVID-19 antibody testing kit, as well as COVID-19 antigen and antibody testing solutions. The company offers its products to hospitals, clinics, laboratories, and healthcare practitioners through distributors in approximately 75 countries worldwide. Omega Diagnostics Group PLC was founded in 1987 and is headquartered in Alva, the United Kingdom.
URL
https://www.omegadx.com/
IPO date
Mar 18, 2004
Employees
91
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
7,546
-11.63%
8,539
-2.24%
Cost of revenue
10,286
9,131
Unusual Expense (Income)
NOPBT
(2,740)
(592)
NOPBT Margin
Operating Taxes
(80)
459
Tax Rate
NOPAT
(2,660)
(1,051)
Net income
(3,860)
173.95%
(1,409)
-33.04%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,200
68
BB yield
-30.61%
-0.94%
Debt
Debt current
55
296
Long-term debt
42
189
Deferred revenue
2,500
2,500
Other long-term liabilities
Net debt
(5,018)
(1,120)
Cash flow
Cash from operating activities
(3,152)
(3,229)
CAPEX
(153)
(1,478)
Cash from investing activities
5,181
(493)
Cash from financing activities
1,486
(502)
FCF
3,981
(3,401)
Balance
Cash
5,115
1,605
Long term investments
Excess cash
4,738
1,178
Stockholders' equity
(15,075)
(13,493)
Invested Capital
27,600
28,179
ROIC
ROCE
EV
Common stock shares outstanding
231,839
186,998
Price
0.03
-19.48%
0.04
-95.22%
Market cap
7,187
-0.17%
7,199
-94.95%
EV
2,169
6,079
EBITDA
(2,149)
697
EV/EBITDA
8.72
Interest
13
21
Interest/NOPBT